Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration

Table 1

The relationship between the expression of PTCD1 and various clinicopathological variables in the TCGA database.

Characteristics	PTCD1 expression	PTCD1 expression	Low	High	-value
Total		405	59	346
Age (years)	≤65	160	25 (6.2%)	135 (33.3%)	0.626
	>65	245	34 (8.4%)	211 (52.1%)
Sex	Male	298	44 (10.9%)	254 (62.7%)	0.851
	Female	107	15 (3.7%)	92 (22.7%)
Pathological stage	Stage I	2	0 (0%)	2 (0.5%)	0.001
	Stage II	129	7 (1.7%)	122 (30.1%)
	Stage III	139	23 (5.7%)	116 (28.6%)
	Stage IV	133	29 (7.2%)	104 (25.7%)
Histologic grade	High grade	382	59 (14.6%)	323 (79.8%)	0.057
	Low grade	20	0 (0%)	20 (4.9%)
T stage	T1	3	0 (0%)	3 (0.7%)	0.193
	T2	118	12 (3.0%)	106 (26.2%)
	T3	193	35 (8.6%)	158 (39.0%)
	T4	57	11 (2.7%)	46 (11.4%)
N stage	N0	235	29 (7.2%)	206 (50.9%)	0.031
	N1	46	12 (3.0%)	34 (8.4%)
	N2	75	16 (4.0%)	59 (14.6%)
	N3	7	0 (0%)	7 (1.7%)
M stage	M0	195	26 (6.4%)	169 (41.7%)	0.648
	M1	11	2 (0.5%)	9 (22.2%)
Survival status	Alive	249	27 (6.7%)	222 (54.8%)	0.007
	Dead	156	32 (7.9%)	124 (30.2%)
PTCD1 level (mean ± SD)		1.83 ± 0.75	0.95 ± 0.12	1.98 ± 0.71	<0.0001

SD: standard deviation. are shown in bold.